SCHEDULE: Citadel Discloses 5.5% Stake in Acrivon Therapeutics

Citadel and its affiliates, including Kenneth Griffin, have disclosed a combined beneficial ownership of 5.5% in Acrivon Therapeutics, Inc. common stock.

Summary

• Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC collectively beneficially own 1,541,326 shares of Acrivon Therapeutics, Inc., representing 4.9% of the outstanding common stock.
• Citadel Securities LLC, Citadel Securities Group LP, and Citadel Securities GP LLC collectively beneficially own 180,541 shares, representing 0.6% of the outstanding common stock.
• Kenneth Griffin, through his control over the various Citadel entities, beneficially owns an aggregate of 1,721,867 shares, which constitutes 5.5% of Acrivon Therapeutics, Inc.'s common stock.
• The beneficial ownership is based on 31,555,126 shares outstanding as of November 7, 2025, as reported in the issuer's Form 10-Q filed on November 13, 2025.
• The shares were not acquired for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 6

Explanation: The filing itself is a neutral disclosure of beneficial ownership. However, the presence of a significant stake by a major institutional investor like Citadel could be interpreted as a moderately positive signal by the market, indicating institutional interest in Acrivon Therapeutics.

Positives

• A prominent institutional investor, Citadel, has taken a significant stake in Acrivon Therapeutics, which may be interpreted by some as a vote of confidence in the company's future prospects.

Future Outlook

NA

Industry Context

This Schedule 13G filing indicates that a major hedge fund and market maker, Citadel, has established a significant passive investment in Acrivon Therapeutics. Such disclosures are common for institutional investors crossing the 5% beneficial ownership threshold, signaling their position in a company without necessarily implying an intent to influence management or control. For a biotechnology company like Acrivon Therapeutics, attracting investment from prominent firms like Citadel can sometimes be viewed positively by the market, suggesting institutional interest in its pipeline or market potential.

Stakeholder Impact

• Shareholders: Existing shareholders may view Citadel's significant stake as a positive indicator of institutional confidence, potentially leading to increased investor interest and share price stability or appreciation.
• Company Management: The company's management will be aware of a major institutional investor holding a significant, albeit passive, stake, which could influence strategic considerations, though the filing explicitly states no intent to control.

Key Dates

Recommendation

The filing indicates a significant, passive stake by a major institutional investor (Citadel) in Acrivon Therapeutics. While this can be a positive signal of institutional interest, a Schedule 13G filing itself does not provide fundamental financial or operational data to warrant a 'buy' or 'sell' recommendation. It primarily confirms a notable ownership position. Therefore, a 'hold' recommendation is appropriate, suggesting investors maintain their current position while awaiting further operational or financial updates from the company.

Keywords

Acrivon Therapeutics, Citadel, Kenneth Griffin, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Biotechnology, Healthcare